Journal of Neuro-Oncology

, Volume 103, Issue 3, pp 739–743

High-dose intravenous rituximab for multifocal, monomorphic primary central nervous system posttransplant lymphoproliferative disorder


  • A. Patrick
    • Department of MedicineSt. Vincent Hospital
  • A. Wee
    • Department of Kidney TransplantationSt. Vincent Hospital
  • A. Hedderman
    • Department of MedicineSt. Vincent Hospital
  • D. Wilson
    • Department of PathologySt. Vincent Hospital
  • J. Weiss
    • Department of MedicineSt. Vincent Hospital
    • Department of Medicine/NephrologySt. Vincent Hospital
Case Report

DOI: 10.1007/s11060-010-0425-0

Cite this article as:
Patrick, A., Wee, A., Hedderman, A. et al. J Neurooncol (2011) 103: 739. doi:10.1007/s11060-010-0425-0


Primary central nervous system (CNS) posttransplant lymphoproliferative disorder (PTLD) is a well-recognized but rare complication of solid organ transplantation. Most of these disorders are B-cell in origin and generally carry poor prognosis. Rituximab, an anti-CD20 monoclonal antibody, has been used effectively in patients with systemic PTLD. However, its role in primary CNS PTLD is doubtful because it does not cross blood–brain barrier efficiently (<5%). Also, mechanisms, by which rituximab operates are not optimally effective in CNS. Here, we describe a renal transplant patient with monomorphic, multifocal, CD20-positive, primary B-cell CNS PTLD, who was treated with high-dose intravenous rituximab given in dose-escalation protocol, which has been used effectively for the patients with chronic lymphocytic leukemia. At 1-year follow-up, magnetic resonance imaging (MRI) showed complete resolution. High-dose rituximab may have a role in highly selected patients with primary CNS PTLD.


Posttransplant lymphoproliferative disorderPrimary CNS PTLDRituximabKidney transplantation

Copyright information

© Springer Science+Business Media, LLC. 2010